Singapore, Singapore

Uttam Surana

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Uttam Surana: Innovator in Antisense Oligonucleotides

Introduction

Uttam Surana is a notable inventor based in Singapore, SG. He has made significant contributions to the field of biotechnology, particularly in the development of antisense oligonucleotides. His work focuses on innovative methods for modulating the activity of glycine decarboxylase (GLDC), which has implications for cancer treatment.

Latest Patents

Uttam Surana holds 1 patent related to antisense oligonucleotides. This invention pertains to the modulation of GLDC activity, specifically through antisense oligonucleotides that can induce exon skipping of RNA. The patent also includes claims for pharmaceutical compositions, kits, and methods for treating cancer using these oligonucleotides. Furthermore, it provides a method for aiding in the categorization or prognosis of cancer by assessing GLDC nucleic acid, protein, or activity levels in patient-derived samples.

Career Highlights

Uttam Surana is affiliated with the Agency for Science, Technology and Research, where he continues to advance his research in biotechnology. His work is pivotal in exploring new therapeutic strategies for cancer treatment, showcasing his commitment to innovation in the medical field.

Collaborations

Uttam collaborates with esteemed colleagues such as Dave Keng Boon Wee and Jing Lin. Their combined expertise contributes to the advancement of research in antisense oligonucleotides and cancer therapies.

Conclusion

Uttam Surana's innovative work in antisense oligonucleotides represents a significant advancement in cancer treatment methodologies. His contributions to biotechnology are paving the way for new therapeutic strategies that could improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…